Skip to main content
Premium Trial:

Request an Annual Quote

Transposagen Expands License to DNA Transposon Tech

NEW YORK (GenomeWeb News) — Transposagen Biopharmaceuticals said today that it has expanded its license for DNA transposon technology to cover nearly all commercial applications, including as a tool for drug and biomarker discovery.

The intellectual property for the transposon technology, called piggyBac, is jointly owned by the University of Notre Dame, the University of Florida, and the US Department of Agriculture.

As part of the deal, Transposagen will be responsible for distribution of piggyBac to researchers working in academia and other non-profit institutes, and will also control commercial sublicenses.

"We will now be able to provide piggyBac to pharmaceutical companies as a novel tool for drug and biomarker discovery," Eric Ostertag, CEO of Transposagen, said in a statement.

Transposagen, based in Lexington, Ky., said that it has been using the piggyBac technology to create its TKO Knockout rat models, which have a single gene disruption and mimic human disease states.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.